Spanish Red Biotech Pipeline

MSD

Pembrolizumab

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma.
Phase: 3Phase III in Spain, 2Phase II, 1Phase I